Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

Devalingam Mahalingam, Ernest C. Medina, Juan A. Esquivel, Claudia M. Espitia, Sabrina Smith, Kelli Oberheu, Ronan Swords, Kevin R. Kelly, Monica M. Mita, Alain C. Mita, Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Purpose: The mammalian target of rapamycin (mTOR) inhibitor temsirolimus has exhibited promising anticancer activity for the treatment of renal cell cancers (RCC). Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus. Experimental Design: The sensitivity of RCC cell lines to the combination of temsirolimus and vorinostat was determined by measuring cell viability, clonogenic survival, and apoptosis. The effects of this combination on survivin levels were determined in vitro and in vivo. Survivin expression was silenced using small interfering RNA to evaluate its role in determining sensitivity to temsirolimus and vorinostat. The effect of the combination on angiogenesis was also determined in RCC xenograft models. Results: Vorinostat synergistically improved the anticancer activity of temsirolimus in a panel of RCC cell lines in vitro and in two xenograft models in vivo. While each single agent led to a modest decrease in survivin levels, the combination dramatically reduced its expression, which correlated with an induction of apoptosis. Silencing survivin levels induced apoptosis and significantly improved the efficacy of temsirolimus and vorinostat. In addition, the temsirolimus/vorinostat combination led to a strong reduction in angiogenesis. Conclusions: Vorinostat augmented the anticancer activity of temsirolimus in both in vitro and in vivo models of RCC. The effectiveness of the combination was due to a decrease in survivin levels and corresponding induction of apoptosis, and enhanced inhibition of angiogenesis. Targeting survivin may be a promising therapeutic strategy to improve RCC therapy.

Original languageEnglish (US)
Pages (from-to)141-153
Number of pages13
JournalClinical Cancer Research
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Renal Cell Carcinoma
Apoptosis
Heterografts
Cell Line
Histone Deacetylase Inhibitors
temsirolimus
vorinostat
Sirolimus
Cell- and Tissue-Based Therapy
Drug Resistance
Small Interfering RNA
Cell Survival
Research Design
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mahalingam, D., Medina, E. C., Esquivel, J. A., Espitia, C. M., Smith, S., Oberheu, K., ... Nawrocki, S. T. (2010). Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clinical Cancer Research, 16(1), 141-153. https://doi.org/10.1158/1078-0432.CCR-09-1385

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. / Mahalingam, Devalingam; Medina, Ernest C.; Esquivel, Juan A.; Espitia, Claudia M.; Smith, Sabrina; Oberheu, Kelli; Swords, Ronan; Kelly, Kevin R.; Mita, Monica M.; Mita, Alain C.; Carew, Jennifer S.; Giles, Francis J.; Nawrocki, Steffan T.

In: Clinical Cancer Research, Vol. 16, No. 1, 01.01.2010, p. 141-153.

Research output: Contribution to journalArticle

Mahalingam, D, Medina, EC, Esquivel, JA, Espitia, CM, Smith, S, Oberheu, K, Swords, R, Kelly, KR, Mita, MM, Mita, AC, Carew, JS, Giles, FJ & Nawrocki, ST 2010, 'Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels', Clinical Cancer Research, vol. 16, no. 1, pp. 141-153. https://doi.org/10.1158/1078-0432.CCR-09-1385
Mahalingam, Devalingam ; Medina, Ernest C. ; Esquivel, Juan A. ; Espitia, Claudia M. ; Smith, Sabrina ; Oberheu, Kelli ; Swords, Ronan ; Kelly, Kevin R. ; Mita, Monica M. ; Mita, Alain C. ; Carew, Jennifer S. ; Giles, Francis J. ; Nawrocki, Steffan T. / Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 1. pp. 141-153.
@article{6ae5c1143f704c1db44c4d259866248a,
title = "Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels",
abstract = "Purpose: The mammalian target of rapamycin (mTOR) inhibitor temsirolimus has exhibited promising anticancer activity for the treatment of renal cell cancers (RCC). Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus. Experimental Design: The sensitivity of RCC cell lines to the combination of temsirolimus and vorinostat was determined by measuring cell viability, clonogenic survival, and apoptosis. The effects of this combination on survivin levels were determined in vitro and in vivo. Survivin expression was silenced using small interfering RNA to evaluate its role in determining sensitivity to temsirolimus and vorinostat. The effect of the combination on angiogenesis was also determined in RCC xenograft models. Results: Vorinostat synergistically improved the anticancer activity of temsirolimus in a panel of RCC cell lines in vitro and in two xenograft models in vivo. While each single agent led to a modest decrease in survivin levels, the combination dramatically reduced its expression, which correlated with an induction of apoptosis. Silencing survivin levels induced apoptosis and significantly improved the efficacy of temsirolimus and vorinostat. In addition, the temsirolimus/vorinostat combination led to a strong reduction in angiogenesis. Conclusions: Vorinostat augmented the anticancer activity of temsirolimus in both in vitro and in vivo models of RCC. The effectiveness of the combination was due to a decrease in survivin levels and corresponding induction of apoptosis, and enhanced inhibition of angiogenesis. Targeting survivin may be a promising therapeutic strategy to improve RCC therapy.",
author = "Devalingam Mahalingam and Medina, {Ernest C.} and Esquivel, {Juan A.} and Espitia, {Claudia M.} and Sabrina Smith and Kelli Oberheu and Ronan Swords and Kelly, {Kevin R.} and Mita, {Monica M.} and Mita, {Alain C.} and Carew, {Jennifer S.} and Giles, {Francis J.} and Nawrocki, {Steffan T.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1385",
language = "English (US)",
volume = "16",
pages = "141--153",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

AU - Mahalingam, Devalingam

AU - Medina, Ernest C.

AU - Esquivel, Juan A.

AU - Espitia, Claudia M.

AU - Smith, Sabrina

AU - Oberheu, Kelli

AU - Swords, Ronan

AU - Kelly, Kevin R.

AU - Mita, Monica M.

AU - Mita, Alain C.

AU - Carew, Jennifer S.

AU - Giles, Francis J.

AU - Nawrocki, Steffan T.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Purpose: The mammalian target of rapamycin (mTOR) inhibitor temsirolimus has exhibited promising anticancer activity for the treatment of renal cell cancers (RCC). Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus. Experimental Design: The sensitivity of RCC cell lines to the combination of temsirolimus and vorinostat was determined by measuring cell viability, clonogenic survival, and apoptosis. The effects of this combination on survivin levels were determined in vitro and in vivo. Survivin expression was silenced using small interfering RNA to evaluate its role in determining sensitivity to temsirolimus and vorinostat. The effect of the combination on angiogenesis was also determined in RCC xenograft models. Results: Vorinostat synergistically improved the anticancer activity of temsirolimus in a panel of RCC cell lines in vitro and in two xenograft models in vivo. While each single agent led to a modest decrease in survivin levels, the combination dramatically reduced its expression, which correlated with an induction of apoptosis. Silencing survivin levels induced apoptosis and significantly improved the efficacy of temsirolimus and vorinostat. In addition, the temsirolimus/vorinostat combination led to a strong reduction in angiogenesis. Conclusions: Vorinostat augmented the anticancer activity of temsirolimus in both in vitro and in vivo models of RCC. The effectiveness of the combination was due to a decrease in survivin levels and corresponding induction of apoptosis, and enhanced inhibition of angiogenesis. Targeting survivin may be a promising therapeutic strategy to improve RCC therapy.

AB - Purpose: The mammalian target of rapamycin (mTOR) inhibitor temsirolimus has exhibited promising anticancer activity for the treatment of renal cell cancers (RCC). Survivin expression has been implicated in drug resistance and reducing its levels with the histone deacetylase (HDAC) inhibitor vorinostat may enhance the anticancer activity of temsirolimus. Experimental Design: The sensitivity of RCC cell lines to the combination of temsirolimus and vorinostat was determined by measuring cell viability, clonogenic survival, and apoptosis. The effects of this combination on survivin levels were determined in vitro and in vivo. Survivin expression was silenced using small interfering RNA to evaluate its role in determining sensitivity to temsirolimus and vorinostat. The effect of the combination on angiogenesis was also determined in RCC xenograft models. Results: Vorinostat synergistically improved the anticancer activity of temsirolimus in a panel of RCC cell lines in vitro and in two xenograft models in vivo. While each single agent led to a modest decrease in survivin levels, the combination dramatically reduced its expression, which correlated with an induction of apoptosis. Silencing survivin levels induced apoptosis and significantly improved the efficacy of temsirolimus and vorinostat. In addition, the temsirolimus/vorinostat combination led to a strong reduction in angiogenesis. Conclusions: Vorinostat augmented the anticancer activity of temsirolimus in both in vitro and in vivo models of RCC. The effectiveness of the combination was due to a decrease in survivin levels and corresponding induction of apoptosis, and enhanced inhibition of angiogenesis. Targeting survivin may be a promising therapeutic strategy to improve RCC therapy.

UR - http://www.scopus.com/inward/record.url?scp=74949089953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949089953&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1385

DO - 10.1158/1078-0432.CCR-09-1385

M3 - Article

C2 - 20028765

AN - SCOPUS:74949089953

VL - 16

SP - 141

EP - 153

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -